๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Pharmacology and safety of phenylpropanolamine

โœ Scribed by David A. Johnson

Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
813 KB
Volume
22
Category
Article
ISSN
0272-4391

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Bioavailability and cardiovascular safet
Bioavailability and cardiovascular safety of dexatrimยฎ (phenylpropanolamine hydrochloride) from a controlledrelease caplet
โœ Leon Shargel; Harold I. Silverman; Peri Cohen; Jerry Brisson; Susana Dennis ๐Ÿ“‚ Article ๐Ÿ“… 1990 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 657 KB

The bioavailability and pharmacokinetics of phenylpropanolamine hydrochloride (PPA HC1) from a DexatrimO controlled-release (CR) caplet and solution was studied. Each subject (n = 12) received either a 75mg PPA HCI CR caplet once daily or a 25 mg PPA HCI solution given three times a day. All subject

Safety pharmacology โ€” A critical perspec
Safety pharmacology โ€” A critical perspective
โœ Roger D. Porsolt ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 84 KB

The present paper critically reviews the notion of safety pharmacology. The term "safety pharmacology" covers those studies carried out to evaluate the risk potential of a novel substance on different biological systems. Tests for other activities could more appropriately come under the heading of "

Manufacturing of Pharmaceutical Proteins
Manufacturing of Pharmaceutical Proteins || Pharmacology and Drug Safety
โœ Behme, Stefan ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› Wiley-VCH Verlag GmbH & Co. KGaA ๐ŸŒ German โš– 226 KB

Risk-benefit evaluation ## Clinical development determines the speed of product development Manufacturing process should be fixed before phase III j139